Marker of Prostate Cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 4, 2014
app pub date -
Jan 29, 2014
filing date -
May 27, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully